TDT

StayLinked Announces Winners of 2022 Partner of the Year Awards

Retrieved on: 
목요일, 4월 20, 2023
Heart, Cork, AIDC, Research, Genesis Partners, Sale, Computer vision, Partner, Machine learning, Artificial intelligence, Growth, ROI, TDT, Software, Nightclub, Online shopping, Video game, Epicor

IRVINE, Calif., April 20, 2023 /PRNewswire/ -- StayLinked Corporation, the leader of innovative terminal emulation solutions for the supply chain industry, is proud to announce the winners of the 2022 Partner of the Year awards.

Key Points: 
  • IRVINE, Calif., April 20, 2023 /PRNewswire/ -- StayLinked Corporation, the leader of innovative terminal emulation solutions for the supply chain industry, is proud to announce the winners of the 2022 Partner of the Year awards.
  • "StayLinked once again saw impressive growth around the globe in 2022," says Ron Caines, President of Sales at StayLinked.
  • "This momentum has been sustained in large part by the members of our impressive partner community who continue to be critical to our success.
  • North American Partner of the Year - SMG3, Schaumburg, Illinois
    Strategic Mobility Group (SMG3) is an innovative technology provider that designs and integrates mobile solutions for enterprises.

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Retrieved on: 
월요일, 4월 3, 2023
Research, FDA, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Priority review, CRISPR, Medical Affairs Bureau, Regenerative Medicine Advanced Therapy, ASH, Civil service commission, Friends, Blas, Health care, FACP, European Medicines Agency, SCD, Clinical trial, Medication, Fast Track, Multimedia, Marketing, EMA, European Commission, CRSP, Physician, Nursing, Maas, Sickle cell disease, Vertex Pharmaceuticals, Orphan, Innovation, CRISPR Therapeutics, Therapy, Regulation of tobacco by the U.S. Food and Drug Administration, Society, TDT, Food, Caregiver, MHRA, Pharmaceutical industry, EU

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the completion of the rolling Biologics License Applications (BLAs) to the U.S. Food and Drug Administration (FDA) for the investigational treatment exagamglogene autotemcel (exa-cel) for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the completion of the rolling Biologics License Applications (BLAs) to the U.S. Food and Drug Administration (FDA) for the investigational treatment exagamglogene autotemcel (exa-cel) for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
  • Data from the Phase 3 studies were most recently presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in December of 2022.
  • In the U.S., exa-cel has been granted Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA for both SCD and TDT.
  • In the U.K., exa-cel has also been granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the MHRA.

Acronis enhances security offerings with Intel® TDT technology

Retrieved on: 
목요일, 3월 23, 2023
Cloud, IDC, Acronis Cyber Protect Home Office, Attack, HDD, Negotiation, Central processing unit, Security, Organization, CPU, Intel, Research, Environment, Memory, TDT, GPU, Computer data storage, Video game, Tourism, Acronis

Acronis is the latest cyber protection company to integrate Intel® TDT to enrich its security products.

Key Points: 
  • Acronis is the latest cyber protection company to integrate Intel® TDT to enrich its security products.
  • Intel® TDT technology allows Acronis cyber protection solutions to free resources while scanning HDD and memory resulting in improved system performance.
  • The innovation of Intel® TDT will be available through Acronis Cyber Protect Cloud, Acronis Cyber Protect, and Acronis Cyber Protect Home Office solutions.
  • “The integration of Intel® TDT into Acronis cyber protection solutions is a logical step to meet the needs of our users, said Patrick Pulvermueller, CEO at Acronis.

13th Gen Intel Core Platform Powers Expanded Intel and ESET Security Offerings

Retrieved on: 
목요일, 3월 23, 2023
VPRO, Learning, Partnership, ESET, Heuristic, Luigi, Core Security Technologies, Intel vPro, CPU, SAN, Intel, Silicon, TDT, Telemetry, Organization, Software, Semiconductor, Computer data storage

SAN DIEGO, March 23, 2023 /PRNewswire/ -- ESET, a global leader in digital security, today announced the availability of ESET endpoint security solutions bolstered by Intel® Threat Detection Technology (Intel® TDT). By combining its advanced multi-layered security software with Intel vPro 9th Gen through the newly launched 13th Gen Intel® Core™ processors, ESET and Intel are delivering a formidable offering for small and medium businesses (SMBs) and enterprises in the fight against ransomware.

Key Points: 
  • The latest generation of Intel vPro devices, combined with ESET endpoint security and Intel TDT, provide SMBs and enterprises with superior ransomware protection
    SAN DIEGO, March 23, 2023 /PRNewswire/ -- ESET , a global leader in digital security, today announced the availability of ESET endpoint security solutions bolstered by Intel® Threat Detection Technology (Intel® TDT).
  • By combining its advanced multi-layered security software with Intel vPro 9th Gen through the newly launched 13th Gen Intel® Core™ processors, ESET and Intel are delivering a formidable offering for small and medium businesses (SMBs) and enterprises in the fight against ransomware.
  • "The universal need for ransomware detection and protection pushed us to innovate endpoint security solutions with Intel that evolve in lockstep with new and novel ransomware variants.
  • Organizations who already run or who purchase compatible Intel hardware have access to advanced ransomware protection when combined with ESET security solutions.

ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents

Retrieved on: 
수요일, 3월 1, 2023
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, IMGN, ImmunoGen, VRTX, Doctor of Philosophy, Sickle cell disease, MD, Medical Affairs Bureau, NYSE, Spacecraft, Patient, Vertex Pharmaceuticals, Yissum Research Development Company of the Hebrew University, Genetic, SCD, ADC, Gene editing, SVP, TDT, Vaccine, Vertex

Following the research period for each target, Vertex will have the option to obtain a worldwide, exclusive license to research, develop, and commercialize conditioning agents employing ImmunoGen's technology for that target.

Key Points: 
  • Following the research period for each target, Vertex will have the option to obtain a worldwide, exclusive license to research, develop, and commercialize conditioning agents employing ImmunoGen's technology for that target.
  • ImmunoGen will retain full rights to the ADC technology for all targets not covered by the Vertex license.
  • ImmunoGen is eligible to receive up to $337 million in option exercise fees and development and commercial milestone payments per target.
  • ImmunoGen will be eligible to receive tiered royalties as a percentage of worldwide commercial sales of novel licensed targeted conditioning agents by Vertex.

Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates

Retrieved on: 
수요일, 2월 22, 2023
Editas Medicine, CMO, Public expenditure, Patent, Gene editing, Bristol Myers Squibb, Ink, Selection, Shore, Collaboration, Health, IPSC, Tissue, Safety, Patient, BMS, Research, HSC, SCD, Paratriathlon, TDT, Pharmaceutical industry, Cryptocurrency

CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today reported business highlights and financial results for the fourth quarter and full year 2022.

Key Points: 
  • In December 2022, Editas Medicine announced positive safety and efficacy data from the first two patients treated in the RUBY trial, suggesting clinical proof-of-concept.
  • Editas Medicine remains on track to dose the first patient in the Phase 1/2 EDITHAL trial for TDT in Q1 2023.
  • Editas Medicine plans to participate in the following investor events:
    The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m.
  • ET to provide and discuss a corporate update and financial results for the fourth quarter and full year of 2022.

Check Point® Software Technologies Enhances Endpoint Security with Intel vPro Platform

Retrieved on: 
목요일, 12월 29, 2022
Software, VPRO, Partnership, Intel vPro, ML, Organization, TDT, SAN, Intel, AI, Silicon, CPU, Risk management

SAN CARLOS, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Check Point® Software Technologies Ltd. (NASDAQ: CHKP), a leading provider of cyber security solutions globally, today announced an extended collaboration with Intel Corporation to offer enhanced anti-ransomware capabilities for Check Point Harmony’s customers.

Key Points: 
  • SAN CARLOS, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Check Point® Software Technologies Ltd. (NASDAQ: CHKP), a leading provider of cyber security solutions globally, today announced an extended collaboration with Intel Corporation to offer enhanced anti-ransomware capabilities for Check Point Harmony’s customers.
  • As ransomware attacks increase in scale and sophistication, integrating the Intel vPro(R) platform’s Threat Detection Technology (TDT) within Check Point Harmony Endpoint helps provide enterprises with processor level anti-ransomware security at both the hardware and software levels, at no extra cost.
  • Data from CPR’s mid-year security report revealed a 42% global increase in cyberattacks placing ransomware as the number one threat.
  • “The Intel vPro platform contains hardware-based security features, including Threat Detection Technology specifically designed to detect ransomware and other advanced threats.

Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease

Retrieved on: 
화요일, 12월 6, 2022
Life, Event, Broad Institute, Clinical trial, Annual report, HBG1, TDT, HBF, HBS, Editas Medicine, Safety, Fetal hemoglobin, Busulfan, Manifest and latent functions and dysfunctions, NCT, Gene editing, CD34, Polymerization, SCD, MD, Harvard University, Sickle cell disease, Mutation, Patent, CRISPR, Senior, Patient, Anemia, Pharmaceutical industry, Vaccine, HBG2

CAMBRIDGE, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced positive, initial clinical data from the first two patients with sickle cell disease (SCD) treated with EDIT-301 in the Phase 1/2 RUBY trial. EDIT-301 is under development for the treatment of severe sickle cell disease. The clinical data includes safety data from the first two patients and efficacy data from the first patient treated.

Key Points: 
  • The clinical data includes safety data from the first two patients and efficacy data from the first patient treated.
  • Additionally, neither patient has experienced any vaso-occlusive events since treatment with EDIT-301, at five and 1.5 months follow up, respectively.
  • EDIT-301 is an experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
  • The RUBY trial is a single-arm, open-label, multi-center Phase 1/2 study designed to assess the safety and efficacy of EDIT-301 in patients with severe sickle cell disease.

Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease

Retrieved on: 
목요일, 12월 1, 2022
TDT, Polymerization, Anemia, HBF, CD34, Event, Mutation, HBG1, Fetal hemoglobin, Patient, SCD, Broad Institute, Harvard University, Sickle cell disease, Patent, HBS, Editas Medicine, NCT, CRISPR, Safety, Manifest and latent functions and dysfunctions, Pharmaceutical industry, Vaccine, HBG2

The clinical data will include safety data from the first two patients and efficacy data from the first patient treated with EDIT-301.

Key Points: 
  • The clinical data will include safety data from the first two patients and efficacy data from the first patient treated with EDIT-301.
  • In sickle cell disease, the red blood cells are misshapen in a sickle shape instead of a typical disc shape.
  • EDIT-301 is an experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
  • The RUBY trial is a single-arm, open-label, multi-center Phase 1/2 study designed to assess the safety and efficacy of EDIT-301 in patients with severe sickle cell disease.

EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell Therapy for Transfusion Dependent β-thalassemia

Retrieved on: 
금요일, 11월 18, 2022
Technology, Research, Genetics, Other Technology, Clinical Trials, Health, General Health, Other Science, Science, Trial of the century, NMPA, TDT, Gene editing, Cas9, National Medical Products Administration, BCL11A, CRISPR, Safety, Translation, IND, RNA, Stem cell, Patient, Pharmaceutical industry, Vaccine

The current standard treatment for TDT requires lifelong packed red blood cell transfusions and iron chelation therapy.

Key Points: 
  • The current standard treatment for TDT requires lifelong packed red blood cell transfusions and iron chelation therapy.
  • ET-01 is designed to achieve a functional cure with a single administration of CRISPR/Cas9 gene-modified autologous hematopoietic stem and progenitor cells.
  • ET-01 is an autologous CD34+ hematopoietic stem/progenitor cell with the erythroid-specific enhancer of the BCL11A gene modified by CRISPR/Cas9.
  • It is the first gene-editing experimental therapy and the first hematopoietic stem cell experimental therapy with IND application approval by China National Medical Products Administration (NMPA).